Matthew Pillar

I like it better on LinkedIn -- follow me there!

[Talking Retail 🇺🇸 @Bob_Hetu]

Retailers increasingly not accepting #cash in the US market. The excuse is a lack of circulation of cash due to #COVID19 does this explanation make sense?

[Matthew Pillar @mattpillar]

I really leaned in to @Allan_L_Shaw's #startup financing knowledge base for this candid conversation on the ins and outs of a special purpose acquisition company, or #SPAC, as a biopharma finance vehicle. He was definitely the man to ask. Via BioProcess O…https://t.co/zCe4290TDG

[Matthew Pillar @mattpillar]

Want to know what process intensification is, the results it drives, the challenges it presents, and how to implement it in your upstream #bioprocessing environment? Join Sonnet BioTherapeutics, Inc. CTO Susan Dexter, single-use an…https://t.co/VlUpKKHnfx https://t.co/VCVehGRscA

[Matthew Pillar @mattpillar]

GSK Senior Clinical Development Manager Michael Mehler shares how GlaxoSmithKline navigates the competition for talent—and how #clinicalresearch directly informs the company's #HR requirements—on this fresh episode of the #business…https://t.co/BosFLYJoCT https://t.co/n62zGxmrzz

[Glympse Bio @GlympseBio]

On the new #BusinessOfBiotech #podcast episode, CEO Dr. @CarolineLoew and @MattPillar discussed the potential of our in-vivo, bioengineered, tunable sensors for diagnostic and prognostic purposes in protease-mediated diseases like #NASH.

Listen now: https://t.co/6madD7zGuZ

[Matthew Pillar @mattpillar]

On this fresh episode of the #businessofbiotech podcast, learn how @organicellTM CSO @MariMitrani and Lab Director Dr. Michael Bellio leverage #bioinformatics to discover the therapeutic potential of perinatal tissue-secreted #exosomes. https://t.co/uIBioXAgZF

[Matthew Pillar @mattpillar]

Ease into the weekend with the latest episode of #businessofbiotech featuring regulatory environment musings with bluebird bio's @scleve14, then tune in Monday for insight from Organicell Regenerative Medicine's @MariMitrani and D…https://t.co/aec3agsGgP https://t.co/bVP4bvxtn0

[Matthew Pillar @mattpillar]

How close are we to manufacturing autologous cell therapies in hospital cleanrooms? Clinical-stage #celltherapy company @Precigen and its CEO Dr. Helen Sabzevari say closer than you might think. #businessofbiotech via @BioProcessOL https://t.co/hQL4y4JD4k

[Matthew Pillar @mattpillar]

Looking for #biotechnology incubation/accelerator space? Whether or not you're in the Valley, this BioProcess Online talk with BioCube-SJ CEO Anthony Gonzalez will give you an idea what good looks like. #biopharma #startups https://t.co/pNHoMAKlJQ

[Matthew Pillar @mattpillar]

Nearly 85% of 18-to-65 year-olds will have at least one strain of #HPV at some point in their life. The #hpvvaccine prevents a host of #cancers, but for whole generations, it came too late. Cue Biopharma CEO Daniel Passeri shares w…https://t.co/2REqWiAGEe https://t.co/jCHr5vqSPN

[Matthew Pillar @mattpillar]

SOTIO CEO Radek Spisek, Ph.D. manages the support of 14 #clinicaltrials for its pipeline of #oncology therapeutics. Learn how we does it on this week's #businessofbiotech via BioProcess Online. https://t.co/nol6vaiqGb

[Matthew Pillar @mattpillar]

"Most people who must climb a ladder do not manage the severity of falling off a ladder. They manage the risk event by taking steps to decrease the likelihood of a fall," says Mark F. Witcher, Ph.D. as he argues to replace RPN with…https://t.co/QDRCdAj88y https://t.co/ZuZGduN3c9

[Matthew Pillar @mattpillar]

This week on The Business of Biotech, Rezolute, Inc. CEO Nevan Charles Elam shares the company's rationale for pursuing congenital #hyperinsulinism and #diabetic macular edema therapeutics by leveraging monoclonal antibodies and di…https://t.co/d0o573cdtE https://t.co/Yfm3QiFZwP

[Precigen @Precigen]

Tune on Monday, March 29, 2021, for the #businessofbiotech #podcast. #Precigen's Helen Sabzevari joins @mattpillar to discuss changing the CAR-T complexity paradigm with an overnight manufacturing process to affect patients in urgent need of timely therapy. $PGEN

[Matthew Pillar @mattpillar]

With backing from heavyweights like Dr. Peter H. Diamandis and @tonyrobbins, Elevian, Inc. CEO Dr. Mark Allen seeks to release the power of a naturally-occurring molecule known as growth differentiation factor 11 to combat age-rela…https://t.co/sQqcJ7MekS https://t.co/KFbK3CsJT1

[Matthew Pillar @mattpillar]

As the CAR T-cell therapy market expands at a fast clip, the dynamic of the "payer layer" is must-follow for the leaders of emerging cell therapy companies. Thanks to Clarivate primary research manager Chris Lewis for sharing this…https://t.co/Xww9A2KXdr https://t.co/WnIdzYVNOc

[Matthew Pillar @mattpillar]

@Allan_L_Shaw is always a great interview on the #businessofbiotech podcast. On today's episode, he pulls from his deep experience as CFO to emerging biotechs to share some of the foundational elements of #biotech success. We're pr…https://t.co/Hpp6lGsIA1 https://t.co/cAl75GWErs

[Matthew Pillar @mattpillar]

Fresh on the heels of its #hypoparathyroidism candidate's foray into phase 1 clinical trials, we're joined by Amolyt Pharma founder and CEO Thierry Abribat for a deep dive into his company's pre-clinical preparation, including fina…https://t.co/8BtlLi0Qpd https://t.co/z5dNY5i6aF

[Matthew Pillar @mattpillar]

In recognition of #internationalwomensday2021, revisit the remarkable women who have joined me on the Business of Biotech podcast, including Edith A. Perez, MD, Smital Shah, Loretta Itri, Kavitha Iyer Rodrigues, @LeslieJWilliams, a…https://t.co/kUcwMHzBay https://t.co/OJ2o9M6lsx

[Matthew Pillar @mattpillar]

Monday's episode of the Business of Biotech podcast will feature Amolyt Pharma CEO Thierry Abribat dishing on his company's clinical preparations. Meanwhile, catch up on recent talks on #artificialintelligence in #genomicmedicine w…https://t.co/coqnbd5Asr https://t.co/OJ2o9M6lsx